8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Feb 27, 2026·SEC
IN8bio, Inc.(INAB)Earnings, Financials & Key Ratios
INAB•NASDAQ
Price updated Jun 16, 2026
AboutIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$17M+37.5%
- Net Income-$19M+36.1%
- EPS (Diluted)-4.44-678.9%
- ROE-92.49%+40.1%
- ROIC-256.03%+5.0%
- Debt/Equity0.10-70.9%
INAB Key Insights
IN8bio, Inc. (INAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 91.8% through buybacks
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 17.8% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INAB Price & Volume
IN8bio, Inc. (INAB) stock price & volume — 10-year historical chart
Loading chart...
INAB Growth Metrics
IN8bio, Inc. (INAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-481.89%
Return on Capital
10 Years-95.08%
5 Years-92.16%
3 Years-108.54%
Last Year-84.55%
INAB Peer Comparison
IN8bio, Inc. (INAB) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 221.46M | 1.90 | -1.65 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ADCT | 126.72M | 1.00 | -0.89 | 14.85% | -173.02% | |||
 IMVT | 6.9B | 33.61 | -12.13 | -68.16% | 0.00 | |||
 AGEN | 124.09M | 2.98 | -876.47 | 10.37% | 52.16% | |||
 CRSP | 5.02B | 52.02 | -8.04 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 231.06M | 2.36 | -1.31 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.63B | 14.56 | -3.82 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.18B | 30.99 | -38.26 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare INAB vs Peers
IN8bio, Inc. (INAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INAB Income Statement
IN8bio, Inc. (INAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 96K | 96K | 0 | 0 | 0 | 2.5M | 0 | 2.5M | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -96K▲ 0% | -96K▲ 0.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -2.5M▲ 0% | 0▲ 100.0% | -2.5M▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | 0% | 100% | - | - | - | 100% | - | - |
Operating Expenses | 2M | 5.07M | 8.56M | 14.65M | 28.52M | 27.84M | 30.44M | 17.36M | 19.16M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.42M | 2.71M | 3.18M | 7.31M | 14.46M | 13.51M | 12.64M | 9.65M | 9.62M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 581K | 2.36M | 5.38M | 7.35M | 14.06M | 16.83M | 16.96M | 10.21M | 9.85M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | -63K | 0 | 0 | 0 | 0 | -2.5M | 838K | -2.5M | -311K |
Operating Income | -2M▲ 0% | -5.13M▼ 156.2% | -8.56M▼ 66.7% | -14.65M▼ 71.2% | -28.52M▼ 94.6% | -30.34M▼ 6.4% | -30.44M▼ 0.3% | -19.86M▲ 34.7% | -18.98M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -156.19% | -66.67% | -71.24% | -94.64% | -6.37% | -0.33% | 34.75% | - |
EBITDA | -1.91M | -5.04M | -8.47M | -13.87M | -27.42M | -27.84M | -27.78M | -17.36M | -17.15M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -164.05% | -68.1% | -63.71% | -97.75% | -1.52% | 0.19% | 37.51% | 30.67% |
D&A (Non-Cash Add-back) | 96K | 96K | 88K | 788K | 1.1M | 2.5M | 2.65M | 2.5M | 1.83M |
EBIT | -2.07M | -5.13M | -8.56M | -14.65M | -28.52M | -30.01M | -29.6M | -19.86M | -14.09M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 230K | 421K | 311K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 230K | 421K | 487K |
Interest Expense | 14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -77K | 0 | 0 | 0 | 0 | 330K | 0 | 421K | 0 |
Pretax Income | -2.08M▲ 0% | -5.13M▼ 146.7% | -8.56M▼ 66.7% | -14.65M▼ 71.2% | -28.52M▼ 94.6% | -30.01M▼ 5.2% | -30.44M▼ 1.4% | -19.44M▲ 36.1% | -18.98M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.08M▲ 0% | -5.13M▼ 146.7% | -8.56M▼ 66.7% | -14.65M▼ 71.2% | -28.52M▼ 94.6% | -30.01M▼ 5.2% | -30.44M▼ 1.4% | -19.44M▲ 36.1% | -18.98M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -146.71% | -66.67% | -71.24% | -94.64% | -5.21% | -1.43% | 36.13% | 30.79% |
Net Income (Continuing) | -2.08M | -5.13M | -8.56M | -14.65M | -28.52M | -30.01M | -30.44M | -19.44M | -18.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.11▲ 0% | -0.27▼ 145.5% | -0.53▼ 96.3% | -0.78▼ 47.2% | -1.36▼ 74.4% | -1.00▲ 26.5% | -0.57▲ 43.0% | -4.44▼ 678.9% | -0.98▲ 0% |
EPS Growth % | - | -145.45% | -96.3% | -47.17% | -74.36% | 26.47% | 43% | -678.95% | -481.89% |
EPS (Basic) | -0.11 | -0.27 | -0.53 | -0.78 | -1.36 | -1.00 | -0.57 | -4.44 | - |
Diluted Shares Outstanding | 19.35M | 19.35M | 19.35M | 18.78M | 20.97M | 29.86M | 53.55M | 4.37M | 19.47M |
Basic Shares Outstanding | 19.35M | 19.35M | 19.35M | 18.78M | 20.97M | 29.86M | 53.55M | 4.37M | 19.47M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
INAB Balance Sheet
IN8bio, Inc. (INAB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.07M | 763K | 18.14M | 38.98M | 22.23M | 24.63M | 12.58M | 27.88M | 22.66M |
Cash & Short-Term Investments | 4.99M | 610K | 17.99M | 37.02M | 18.18M | 21.28M | 11.12M | 27.09M | 21.94M |
Cash Only | 4.99M | 610K | 17.99M | 37.02M | 18.18M | 21.28M | 11.12M | 27.09M | 21.94M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 30K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 57.03 | - | - | - | - | - | - | - | - |
Other Current Assets | 37K | 0 | 0 | 52K | 232K | 270K | 298K | 788K | 721K |
Total Non-Current Assets | 823K | 367K | 2.77M | 3.24M | 10.8M | 9.08M | 8.37M | 4.4M | 3.6M |
Property, Plant & Equipment | 795K | 274K | 186K | 2.83M | 10.3M | 8.57M | 7.83M | 4.04M | 3.25M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 126K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 252K | 256K | 266K | 220K | 764K |
Other Non-Current Assets | 28K | 93K | 2.58M | 409K | 381K | 255K | 275K | 146K | 349K |
Total Assets | 5.89M▲ 0% | 1.13M▼ 80.8% | 20.91M▲ 1750.4% | 42.22M▲ 101.9% | 33.04M▼ 21.8% | 33.71M▲ 2.0% | 20.94M▼ 37.9% | 32.28M▲ 54.1% | 26.27M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -80.83% | 1750.44% | 101.93% | -21.75% | 2.03% | -37.87% | 54.13% | 77.46% |
Total Current Liabilities | 419K | 647K | 2.57M | 2.26M | 5.82M | 5.39M | 3.08M | 3.16M | 2.16M |
Accounts Payable | 419K | 560K | 620K | 395K | 2.09M | 924K | 389K | 309K | 449K |
Days Payables Outstanding | 1.59K | 2.13K | - | - | - | 134.85 | - | 45.1 | - |
Short-Term Debt | 0 | 0 | 174K | 0 | 0 | 0 | 1.65M | 1.22M | 1.03M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 876K | 926K | 1.46M | 1.67M | 1.05M | 1.63M | 681K |
Current Ratio | 12.11x | 1.18x | 7.05x | 17.28x | 3.82x | 4.57x | 4.08x | 8.82x | 10.50x |
Quick Ratio | 12.07x | 1.18x | 7.05x | 17.28x | 3.82x | 4.57x | 4.08x | 8.82x | 10.50x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 829K | 829K | 17K | 1.78M | 4.49M | 3.38M | 3.38M | 1.56M | 1.33M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.56M | 1.33M |
Capital Lease Obligations | 0 | 0 | 0 | 1.78M | 4.49M | 3.38M | 3.38M | 0 | 5.62M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 829K | 829K | 17K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.25M | 1.48M | 2.59M | 4.04M | 10.31M | 8.77M | 6.47M | 4.72M | 3.48M |
Total Debt | 0 | 0 | 174K | 2.41M | 5.87M | 4.89M | 5.03M | 2.78M | 2.35M |
Net Debt | -4.99M | -610K | -17.82M | -34.61M | -12.31M | -16.39M | -6.09M | -24.31M | -19.59M |
Debt / Equity | - | - | 0.01x | 0.06x | 0.26x | 0.20x | 0.35x | 0.10x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.14x |
Interest Coverage | -147.64x | - | - | - | - | - | - | - | - |
Total Equity | 4.65M▲ 0% | -346K▼ 107.4% | 18.32M▲ 5395.1% | 38.18M▲ 108.4% | 22.73M▼ 40.5% | 24.94M▲ 9.7% | 14.48M▼ 41.9% | 27.56M▲ 90.3% | 22.78M▲ 0% |
Equity Growth % | - | -107.45% | 5395.09% | 108.41% | -40.47% | 9.7% | -41.94% | 90.34% | 219.96% |
Book Value per Share | 0.24 | -0.02 | 0.95 | 2.03 | 1.08 | 0.83 | 0.27 | 6.30 | 1.17 |
Total Shareholders' Equity | 4.65M | -346K | 18.32M | 38.18M | 22.73M | 24.94M | 14.48M | 27.56M | 22.78M |
Common Stock | 1K | 1K | 1K | 2K | 3K | 4K | 7K | 10K | 10K |
Retained Earnings | -4.35M | -9.48M | -18.04M | -32.69M | -61.21M | -91.22M | -121.66M | -141.1M | -146.19M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INAB Cash Flow Statement
IN8bio, Inc. (INAB) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.77M | -4.8M | -7.13M | -13.51M | -24.12M | -23.34M | -24.15M | -12.71M | -14.54M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -73.38% | -48.57% | -89.39% | -78.55% | 3.24% | -3.47% | 47.36% | 66.3% |
Net Income | -2.08M | -5.13M | -8.56M | -14.65M | -28.52M | -30.01M | -30.44M | -19.44M | -18.98M |
Depreciation & Amortization | 96K | 96K | 88K | 788K | 1.1M | 2.5M | 2.65M | 1.77M | 1.83M |
Stock-Based Compensation | 31K | 76K | 357K | 2.19M | 3.47M | 4.37M | 5M | 3.19M | 2.07M |
Deferred Taxes | 0 | 0 | 0 | -541K | -4.16M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 70K | 68K | 368K | 541K | 4.16M | 0 | 45K | 730K | 434K |
Working Capital Changes | -885K | 93K | 611K | -1.84M | -170K | -204K | -1.41M | 1.04M | 110K |
Change in Receivables | -30K | 30K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -152K | 141K | -160K | -319K | 1.51M | -981K | -535K | -80K | -126K |
Cash from Investing | -757K | 356K | 0 | -309K | -3.71M | -600K | -187K | 0 | -9K |
Capital Expenditures | -757K | -330K | 0 | -309K | -3.71M | -600K | -104K | 0 | -9K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 686K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -83K | 0 | 0 |
Cash from Financing | 8.5M | 65K | 24.52M | 32.95M | 8.99M | 27.04M | 14.18M | 28.64M | 24.55M |
Debt Issued (Net) | 1.26M | 0 | 174K | -709K | -615K | -798K | -794K | -693K | -468K |
Equity Issued (Net) | 0 | 65K | 25.67M | 36.33M | 9.54M | 27.84M | 9.94M | 29.33M | 25.21M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 7.24M | 0 | -1.33M | -2.66M | 61K | 0 | 5.04M | 0 | -195K |
Net Change in Cash | 4.97M▲ 0% | -4.38M▼ 188.0% | 17.38M▲ 496.9% | 19.14M▲ 10.1% | -18.84M▼ 198.4% | 3.1M▲ 116.5% | -10.15M▼ 427.5% | 15.93M▲ 256.9% | 10M▲ 0% |
Free Cash Flow | -3.53M▲ 0% | -5.13M▼ 45.5% | -7.13M▼ 39.0% | -13.82M▼ 93.7% | -27.83M▼ 101.4% | -23.94M▲ 14.0% | -24.25M▼ 1.3% | -12.71M▲ 47.6% | -14.55M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -45.52% | -39.02% | -93.72% | -101.38% | 13.97% | -1.31% | 47.59% | 25.28% |
FCF per Share | -0.18 | -0.27 | -0.37 | -0.74 | -1.33 | -0.80 | -0.45 | -2.91 | -0.75 |
FCF Conversion (FCF/Net Income) | 1.33x | 0.94x | 0.83x | 0.92x | 0.85x | 0.78x | 0.79x | 0.65x | 0.77x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INAB Key Ratios
IN8bio, Inc. (INAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -238.74% | -95.21% | -51.87% | -93.64% | -125.9% | -154.44% | -92.49% | -96.39% |
| Return on Invested Capital (ROIC) | - | - | -539.64% | -305.67% | -239.86% | -269.58% | -256.03% | -334.35% |
| Debt / Equity | - | 0.01x | 0.06x | 0.26x | 0.20x | 0.35x | 0.10x | 0.10x |
| FCF Conversion | 0.94x | 0.83x | 0.92x | 0.85x | 0.78x | 0.79x | 0.65x | 0.77x |
Related:INAB Dividend History·INAB Revenue History·INAB Price History·INAB P/E History·INAB Financial Ratios·INAB Institutional Holders
INAB SEC Filings & Documents
IN8bio, Inc. (INAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
INAB Frequently Asked Questions
IN8bio, Inc. (INAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IN8bio, Inc. (INAB) grew revenue by 0.0% over the past year. Growth has been modest.
IN8bio, Inc. (INAB) reported a net loss of $19.0M for fiscal year 2025.
Dividend & Returns
IN8bio, Inc. (INAB) has a return on equity (ROE) of -92.5%. Negative ROE indicates the company is unprofitable.
IN8bio, Inc. (INAB) had negative free cash flow of $14.5M in fiscal year 2025, likely due to heavy capital investments.